Patent ID: 8460663
Filing Date: 2013-06-11
Classification: A61K,A61P,C07K

Abstract:
1. A method for preventing a symptom of a respiratory syncytial virus (RSV) infection, comprising administering intramuscularly to a human infant 15 mg/kg of an aqueous palivizumab formulation comprising, in distilled water: (a) 103±3 mg/ml of palivizumab or an antigen-binding fragment thereof; (b) histidine at a concentration of about 25 mM, and (c) glycine at a concentration of about 1.6 mM, wherein the palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for 15 months as determined by high performance size exclusion chromatography (HPSEC) and the formulation has a pH of about 6.0.